The use of monoclonal antibodies against TNF-α has shown mixed results, some proven successful in inducing remission in cases of IBD (248), but also at the cost of adverse events and high number of non-responders over time (249, 250). This evidence concerns the gene TNF and inflammatory bowel disease.